vaccine

Harvard's DoriVac platform, built from self-assembling DNA nanostructures, matches mRNA vaccine immune responses while eliminating cold chain requirements, a Nature Biomedical Engineering study shows.

ARMR Sciences begins Phase 1 trials of a vaccine that trains the immune system to intercept fentanyl before it reaches the brain, a preventive approach with no precedent in addiction medicine.

Five-year KEYNOTE-942 trial data show Moderna and Merck's individualized neoantigen mRNA vaccine maintains a 49% reduction in melanoma recurrence or death.